Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Reversal of CSF HIV-1 Escape During Treatment of HIV-Associated Cryptococcal Meningitis in Botswana

Nametso Kelentse
ORCID logo ,
Sikhulile Moyo
,
Kesaobaka Molebatsi
,
Olorato Morerinyane
,
Shatho Bitsang
,
Ontlametse T. Bareng
,
Kwana Lechiile
,
Tshepo B. Leeme
,
David S. Lawrence
ORCID logo ,
Ishmael Kasvosve
ORCID logo ,
Rosemary Musonda
,
Mosepele Mosepele
,
Thomas S. Harrison
,
Joseph N. Jarvis
,
Simani Gaseitsiwe
*
Version 1 : Received: 22 May 2022 / Approved: 24 May 2022 / Online: 24 May 2022 (04:20:08 CEST)

A peer-reviewed article of this Preprint also exists.

Kelentse, N.; Moyo, S.; Molebatsi, K.; Morerinyane, O.; Bitsang, S.; Bareng, O.T.; Lechiile, K.; Leeme, T.B.; Lawrence, D.S.; Kasvosve, I.; Musonda, R.; Mosepele, M.; Harrison, T.S.; Jarvis, J.N.; Gaseitsiwe, S. Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. Biomedicines 2022, 10, 1399. Kelentse, N.; Moyo, S.; Molebatsi, K.; Morerinyane, O.; Bitsang, S.; Bareng, O.T.; Lechiile, K.; Leeme, T.B.; Lawrence, D.S.; Kasvosve, I.; Musonda, R.; Mosepele, M.; Harrison, T.S.; Jarvis, J.N.; Gaseitsiwe, S. Reversal of CSF HIV-1 Escape during Treatment of HIV-Associated Cryptococcal Meningitis in Botswana. Biomedicines 2022, 10, 1399.

Abstract

Cerebrospinal fluid (CSF) viral escape has been poorly described among people with HIV-associated cryptococcal meningitis. We determined the prevalence of CSF viral escape and HIV-1 viral load (VL) trajectories in individuals treated for HIV-associated cryptococcal meningitis. A retrospective longitudinal study was performed using paired CSF and plasma collected prior to and during the antifungal treatment of 83 participants recruited at the Botswana site of the phase-3 AMBITION-cm trial (2018-2021). HIV-1 RNA levels were quantified then CSF viral escape (CSF HIV-1 RNA ≥ 0.5 log10 higher than plasma) and HIV-1 VL trajectories were assessed. CSF viral escape occurred in 20/62 (32.3%; 95% confidence interval [CI]: 21.9%-44.6%), 13/52 (25.0%; 95% CI: 15.2%-38.2%) and 1/33 (3.0%; 95% CI: 0.16%-15.3%) participants at days 1, 7 and 14 respectively. CSF viral escape was significantly lower on day 14 compared to days 1 and 7, p=0.003 and p=0.02, respectively. HIV-1 VL de-creased significantly from day 1 to day 14 post antifungal therapy in the CSF but not in the plasma (OR, 0.56; 95% CI: 0.41-0.77; p<0.001). CSF viral escape is high among individuals presenting with HIV-associated cryptococcal meningitis; however, antifungal therapy may reverse this, highlighting the importance of rapid initiation of antifungal therapy in these patients.

Keywords

HIV; cryptococcal meningitis; HIV-1 viral load; cerebrospinal fluid (CSF) viral escape; Botswana

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.